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Abstract  
Background and aims: To assess how far the greater effectiveness of varenicline over nicotine 
replacement therapy is moderated by characteristics of the smokers or setting in clinical practice. 
Design:  Observational data between 2013 and 2016 arising from users of Quit-51 smoking cessation 
service across 11 different health regions in England. 
Participants: Clients of smoking cessation service. 
Measurements: 4-week Carbon monoxide - validated (primary response) and 12-week  self-reported 
(secondary) quit success/failure.  
Methods: We used observational data from 22,472 treatment episodes between 2013 and 2016 
from smoking cessation services in England to assess whether differences between varenicline and 
NRT in 4-week biochemically validated and 12-week  self-reported quit rates were moderated by a 
set of smoker and setting characteristics: level of social deprivation, age, gender, ethnic group, 
nicotine dependence, and treatment context. From the above, 15,640 episodes were analysed in 
relation to 4-week quit and 14,273 episodes at 12 weeks. All two-way interactions involving 
pharmacotherapy were fitted in addition to the main effects and a parsimonious model identified 
using a backwards stepwise selection procedure. 
Findings: At both follow-up points, varenicline was associated with higher success rates overall 
(adjusted odds ratio varenicline vs NRT = 1.82 [95%CI 1.61, 2.06] and 2.58 [95%CI 2.26,2.94] at 4 and 
12 weeks respectively).  At 12 weeks, the relative benefits of varenicline were found to be influenced 
by the setting in which advice was provided (adjusted OR for varenicline × pharmacy setting = 0.53, 
[95% CI 0.42, 0.69] and for varenicline × General Practice setting = 0.79, [95% CI 0.64,0.98] against a 
baseline of 1 for varenicline × community setting). The same trends were evident at 4 weeks but this 
did not translate to statistical significance. There was not conclusive proof for moderating effects 
with respect to other variables considered.Conclusions: Varenicline use is associated with higher 
smoking cessation rates than NRT in routine clinical practice, irrespective of a wide range of smoker 
characteristics but the difference is less in certain intervention settings, most notably pharmacy and 
GP practice, than the most common prescription of a community setting. 
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Introduction 
The UK has a national network of smoking cessation services [1]. Similar kinds of support are 
available in other countries [2]. A range of factors show association with higher success rates in 
these kinds of services [3]. Among these is the use of varenicline in contrast to nicotine replacement 
therapy (NRT). However, it is not clear how far the relative benefits of varenicline are influenced by 
characteristics of smokers or aspects of service delivery. This study looks at the impact on treatment 
effect of a range of covariates recorded at the individual, temporal and service level. 
According to National Institute for Healthcare Excellence (NICE) and National Centre for Smoking 
Cessation Training (NCSCT) guidelines [4, 5], smoking cessation services provide a programme of 
counselling sessions with accredited advisers supplemented by tailored pharmacotherapy, using 
treatments which have shown efficacy in relation to placebo/no treatment [6, 7]. Most often, clients 
are provided with NRT including skin patches and an oral product [8]. The concurrent use of two 
forms of NRT has been found to yield improved success rates [3, 9]. Other treatments are available 
in the form of varenicline (Champix) and bupropion (Zyban). Varenicline has been found to yield 
higher quit rates than other treatments [10] although combination NRT was estimated to have near 
parity in a network meta-analysis [11]. The performance of varenicline in a real-world setting is less 
well understood, although evidence exists to suggest that the benefits seen in randomised 
controlled trials (RCTs) can be replicated in a clinical setting [12, 13]. 
It is important to provide treatments for smokers that are tailored to their needs. It may be 
hypothesised that the effectiveness of pharmacotherapy is to a degree dependent on client 
characteristics (age, gender, level of dependence). Such effects have been observed in relation to 
varenicline in the treatment of alcohol dependence [14]. Whilst the benefits of pharmacotherapy in 
respect of smoking cessation are well known, the potential moderating effect of other variables is at 
present little understood.  
We used data recorded on clients registered with a  Quit-51 [15] , a provider of smoking cessation 
services in England, to assess whether the increased quit rates expected with varenicline versus NRT 
were moderated by other factors (such as age, gender, ethnic group and features of service 
provision). An earlier analysis of data from Quit-51 focused on interactions with gender including 
treatment [16] The current work takes in approximately six months’ of further data (up to 
September 2015 in previous analysis, now up to March 2016) in addition to records from 7 extra 
regions for which data were not available in earlier analysis. A number of new covariates were 
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considered in analysis including FTND, IMD and ethnicity. The size of the master dataset in the 
current analysis was 22,472 in comparison to 11,394 in the afore-mentioned work. 
Methods 
Participants, Design and Setting: We used data recorded by Quit-51 on clients using the service 
between March 2013 and March 2016 within the following 11 English regions: Leicester, Lincoln, 
Sandwell, Solihull, Stoke, Surrey, East Sussex, Telford & Wrekin, Walsall, West Cheshire and 
Worcester. At the outset, this comprised 22,472 observations, but this number was reduced 
(including two of the original regions) as a result of some records being omitted prior to statistical 
analysis (Figure 1). 
Data recorded by Quit-51 are wide-ranging, including client-level information (age, gender, metrics 
relating to tobacco dependence etc.), details on support provided (pharmacotherapy, whether 
counselling was on a group basis at a GP or pharmacy or one-to-one etc.), information on sessions 
attended (date, duration etc.) in addition to measures of success/failure of quit attempt. The 
primary motivation of this work was to identify the relationship between pharmacotherapy and quit 
success (at 4 and 12 weeks) and to investigate whether this relationship was moderated by other 
covariates. Awareness of such relationships may be informative in deciding on individual treatment 
regimes for users of smoking cessation services. 
Measures: Our primary outcome measure was Carbon Monoxide (CO)–validated quit [17]in line with 
NHS guidelines at 4 weeks and this was supported by analysis of self-reported quit at 12 weeks (CO 
readings were only taken at the 4 week time point). A number of additional variables were extracted 
or derived from master data, namely: gender, age at quit date (4 categories: 13-19 years, 20-39 
years, 40-59 years, 60 years and above), pharmacotherapy (NRT/ varenicline), intervention setting – 
a categorical variable describing the setting in which client met with practitioner for advisory 
sessions (the original categories are described here [18] but these were reduced to community, GP 
practice, pharmacy, Stop Smoking Service [SSS] and other), year, yearly quarter 
(January/February/March = 1, April/May/June = 2, July/August/September = 3, 
October/November/December = 4), ethnic group (6 categories derived from original data -  White; 
British & Irish, White; Other, Asian, Black, Other, Unknown), nicotine dependence based on the 
Fagerstrom Test for Nicotine Dependence, or FTND [19], whereby a higher score denotes greater 
dependence.  
Social deprivation was assessed using the Index of Multiple Deprivation, or IMD [20], which is an 
areal deprivation score mapped to postcode and scored on a scale of 1-10 inclusive, with lower 
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scores indicating greater deprivation.  In order to facilitate interpretation when talking of a 
deprivation effect, these scores were inverted so that 1 = least deprived/most affluent area with 
increasing score indicating a greater degree of deprivation (maximum=10). Summary statistics for 
both deprivation and FTND are presented for each score up to 10 (i.e. as a categorical variable) but 
in statistical analyses these were treated as continuous variables. 
Data preparation: Preliminary restrictions were applied to the master dataset. Instances where 
bupropion had been prescribed were removed as the number (N=80) was considered too low to be 
able to make a meaningful comparison with the other treatments. Clients recorded as pregnant 
were left out of analysis. In some instances, more than one treatment was recorded as having been 
prescribed. These cases were removed as it was not possible to compare treatment effect in 
addition to there being uncertainty as to whether this information had been recorded correctly. 
Cases where age was recorded outside the range 13-89 inclusive were also removed as it was 
considered possible that these may have been misreported. The above restrictions gave rise to a 
dataset of 20,463 observations (Dataset 2, Figure 1) which was used for the derivation of summary 
statistics.    
In addition to the main analysis, frequencies are presented in the subgroups prescribed (i) NRT (ii) 
varenicline for a group of factors which were not considered in regression models. Included here are 
the binary variables “live with other smokers (no/yes)” and “live with children (no/yes)”. 
Furthermore, a number of morbidities were identified from the variable “medical condition” (text 
field consisting of a theoretically unlimited list of conditions) which may have influenced choice of 
treatment. From these, three binary variables were derived: psychological condition (where original 
field included “anxiety disorder”, “schizophrenia”, “depression”, “mental illness”, “manic-depressive 
disorder” or “eating disorder”); heart condition (from “angina”, “heart disease”, “heart attack”, 
“heart failure”, “acute cardiovascular event within the last 4 weeks” or “CHD”) and lung condition 
(from “bronchitis”, “emphysema”, “collapsed lung”, “COPD” or “persistent cough or 
breathlessness”). Whilst these figures may point to imbalance in the two treatment groups, there 
was uncertainty as to the robustness of their recording and none of these were included in 
regression models. 
Four week analysis: Further sequential restrictions were applied before analysis of quit at 4 weeks. 
Specifically (i) removal of observations where the quit date fell after 31/1/16 (ii) omission of records 
where the intervention setting field is empty (iii) retention of either the first chronological 
observation where all analytical data were available or the first chronological observation if no such 
“comprehensive” record was available. The first of these was carried out to ensure as far as possible 
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that 4-week quit information was not incomplete, i.e. that the client was not in the middle of a 
cessation attempt at the time of data compilation. The second step ensured that each individual 
contributed one record only as there was a small degree of client replication as can be ascertained 
from Figure 1.  
Analyses: Analysis was carried out on 4-week CO-validated quit (0/1) using a Generalised Linear 
Mixed Model (GLMM) procedure [21].  Explanatory variables fitted were: gender, age, 
pharmacotherapy, intervention setting, year, yearly quarter, ethnic group, IMD and FTND. A logit 
transform was applied to the response variable (4-week and 12-week quit) and dispersion fixed at 1. 
The region where the client was based was incorporated as an unstructured random effect. A 
backwards stepwise procedure was applied starting with a model including all of the above 
explanatory variables as main effects and all two-way interactions involving pharmacotherapy and 
the other explanatory variables. At each step, the main effect/interaction with the highest p-value 
(based on χ2 Wald tests) was identified and removed from the model if above an a priori threshold of 
0.05. This process was concluded where all remaining effects had p < 0.05, giving rise to a most 
parsimonious model. For clarity of interpretation, three-way interactions were not considered but 
the possibility of their existence cannot be ruled out (or at higher levels) and the final model 
selected should not be interpreted as the “best amongst all models”. Main effects were not 
considered for removal until interactions involving the relevant variable had been eliminated.  
Missing data: By default, a complete-case analytical approach was adopted. Since data were missing 
to varying degrees for a number of variables in the model, the de facto size of the dataset was 
reduced accordingly. The extent of missing data in some cases was sufficient to potentially 
undermine the generalisability of the results. The variables identified as missing a significant level of 
data were (i) pharmacotherapy (ii) FTND (iii) IMD as can be ascertained from Table 1.  
In order to address concerns over possible consequences on the results arising from missing data, 
the optimal model identified from the original analysis was repeated after data were imputed in 
respect of the three variables listed above. Values were imputed through regression based on the 
following explanatory variables: age, gender, occupation, ethnicity and intervention setting. This 
process was repeated three times in order to allow for uncertainty in the imputation process and 
from these, averages were derived of parameter estimates and Wald statistics. Details on the 
imputation are provided in Supplementary File 1. Regression results from the optimal model 
identified were compared between (i) the original dataset and (ii) the same supplemented with 
imputed data as described above. Subject to reasonable agreement in this regard, results presented 
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and inference are based on results arising from analysis of imputed data. For the purposes of 
comparison, the results from original complete-case analyses are presented in Supplementary File 2. 
The same procedure was repeated for analysis of self-reported quit at 12 weeks except that the cut-
off date used for inclusion was now 9/12/15. All analyses were carried out in GenStat 18.0 [22]. 
clientclientclientclientResults 
Table 1 shows the frequencies of records in the different subgroups for key variables, in addition to 
the frequency and percentage of varenicline prescription using the sample that was followed up at 4 
weeks. Table 2 looks at the frequencies of subgroups of potentially influential factors which were 
not included in analysis. 
With respect to the analysis of 4-week CO-validated quit, the selected model retained all main 
effects except ethnic group (and by extension the interaction between ethnic group and treatment). 
Most of these translated to significant effects when imputed data were included in analysis except 
for (i) gender (ii) treatment × intervention setting (iii) treatment × FTND, although the direction of 
these effects was the same in both cases. Model parameters for the analysis of supplemented data 
at this timescale are provided in Table 3. Clients using varenicline were significantly more likely to 
quit than those using NRT (adjusted odds ratio [OR] for a successful quit and 95% confidence interval 
[CI] for varenicline vs NRT = 2.07 [1.85-2.23]). The odds of a successful quit at 4 weeks was found to 
improve progressively with age group (Table 3). Clients who were provided counselling in a 
community setting had a higher quit rate than all other categories and a significantly higher odds 
ratio than all except the “other ” category (Table 3).  The probability of a successful quit was 
observed to decrease with baseline tobacco dependence  and people living in deprived areas were 
less likely to quit than those in more affluent areas (OR and CI below 1 in both instances, see Table 
3).  
 
Although the overall quit rate at 12 weeks was lower than at 4 weeks (mean quit rate was 56.0% and 
28.8%% for 4 and 12 weeks respectively), the overall pattern in terms of odds ratios at 12-week quit 
(Table 4) were broadly similar to the above with a few notable exceptions. The set of variables 
identified by initial complete-case backwards stepwise regression was the same as for 4 weeks 
except for the removal of the interaction between treatment and dependence (FTND). On this 
occasion, all effects were also found to be significant when analysis was repeated on supplemented 
data.   At this time interval, significant differences among the levels associated with the interaction 
between treatment and setting were found (Table 4). This manifested itself through an elevated 
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odds ratio when varenicline was used in conjunction with community setting (all other combinations 
involving varenicline were estimated at less than unity) and consideration of the corresponding 
confidence intervals indicates that this difference was significant in relation to (i) varenicline in 
conjunction with (i) pharmacy (ii) “other” setting categories. . 
Discussion 
In an analysis of data on clients using a smoking cessation service, varenicline use was found to 
improve the odds of a successful quit relative to NRT and furthermore, the magnitude of this 
phenomenon was found to depend on the setting in which counselling was provided when quit was 
measured at 12 weeks. In contrast to  much of the research in this area, the data originate from a 
real-world setting where we might expect these effects to be attenuated in relation to those 
observed in the idealised environment of scientific trials [23]. 
Nicotine replacement therapy was prescribed almost three times more often than varenicline. 
Furthermore, men were prescribed varenicline more often than women. This difference cannot be 
attributed to non-use of this treatment amongst pregnant women [8] as records associated with this 
subgroup were removed from the dataset before analysis. Prescription of varenicline is not 
prescribed to the under 18s  and this is reflected in the low rate of use in the youngest age group. 
Unlike in the other age groups, there are more males than females in the teenage group.  
The difference in quit rate between the two treatments presented here is striking and of a greater 
magnitude than that reported elsewhere at the same [24] and different points in time [25]. 
Comparison of quit rates at specific times is complicated by the fact that the agreed quit date 
coincides with the start of treatment with respect to NRT, but is fixed 8 to 14 days after start of 
treatment for those using varenicline Therefore, there tends to be a longer gap between initial 
registration and 4-week quit date for varenicline users. This difference in the schedule could 
potentially influence estimates of treatment effect in unforeseen ways. For example, the extended 
period between registration and scheduled follow-up dates could hypothetically increase the risk of 
drop-out in the intervening period (although there is no evidence here of that here since the 
cessation rate is higher in varenicline users).   
The chance of quit success was also found to be influenced by the session setting, with the highest 
levels of success seen in relation to community setting at 4 weeks, although this did not emerge as 
the “best” setting at 12 weeks. At both 4 and 12 weeks, GP practice fared worse than other settings. 
The observation that men have a greater chance of quitting than women has been reported 
elsewhere [26, 27] as has the link between socio-economic deprivation and low quit rates [28-30].   
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Statistical analysis of the initial data (pre-imputation) suggested the presence of interactions 
between pharmacotherapy and (i) intervention setting (ii) tobacco dependence at 4 weeks and just 
intervention setting at 12 weeks. However, these effects were no longer found to be statistically 
significant at 4 weeks once imputed data were included. The interaction between treatment and 
setting was significant at 12 weeks after including the additional data and it was notable that at both 
time points the benefit of varenicline was most diminished in conjunction with pharmacy setting. 
The low quit rate associated with varenicline in conjunction with pharmacy suggest that more 
intensive support may be required for clients within this treatment pathway in order for the effects 
of this medication to be optimised. 
 
 
In contrast, the relatively low quit rates observed in relation to varenicline in conjunction with 
pharmacy suggest that more support may be required for clients within this treatment pathway. 
In an age where the internet is increasingly accessible, there may in future be greater emphasis on 
online smoking cessation services [31] which have been found to increase quit rates, especially in 
conjunction with medication such as varenicline [27]. This may represent an appealing option for a 
younger age group who are generally more engaged with internet media and in the current service 
do not achieve as high quit rates as older age groups..  
Even allowing for the significant interactions, varenicline was associated with higher quit rates across 
the different levels of all factors. Thus whilst there may be counter-arguments to prescribing 
varenicline to individuals where there is concern over severity of side-effects or possible health 
consequences (e.g. in the case of teenage smokers) there is no evidence here to suggest that NRT 
will outperform varenicline in any of these subgroups in enhancing cessation rates . 
Although not included in analysis, summary statistics show a disproportionate tendency to 
prescription of NRT rather than varenicline in clients diagnosed with a psychological condition (but 
not notably in relation to other additional factors considered). This may have had some bearing on 
the results, although the number of clients in this group is relatively small and the discrepancy in 
frequency not great (approximately 4%). With the data being observational in nature, the potentially 
distorting effects of covariates, both measured and unmeasured, cannot be ignored and further 
evidence from similar analysis of extraneous data would be valuable in drawing conclusions 
regarding treatment effects and associated moderators. 
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There are likely to be interactive effects in relation to a range of variables in addition to those 
considered here, for example gender and financial strain as identified by Reitzel et al. [32]. This 
provides scope for further research, both through RCTs and observational cohorts.  This could also 
incorporate further experimentation around an optimal regime for the various pharmaceutical 
agents. For example, Hajek et al. [33] observed that both quit success and a number of measures 
recorded in relation to nicotine withdrawal discomfort showed favourable results when smokers 
were preloaded with varenicline for 4 weeks before the quit date, a period longer than the current 
prescription in the UK of 2 weeks. It would also be instructive to learn how such variations in 
medication regime are moderated (if at all) by other factors. 
  Conclusions 
In an analysis of data from a smoking cessation service, varenicline was found to outperform NRT as 
an aid to cessation, men quit with higher probability than women and the percentage of successful 
quits increased with age. The setting for counselling with practitioner was also found to influence 
the chance of quitting. Furthermore, significant interactions were observed between (i) 
pharmacotherapy and setting. Varenicline was found to be least effective in conjunction with  
pharmacy intervention setting. Notwithstanding interactions, varenicline was found to enhance quit 
rates relative to NRT across all subgroups, suggesting a universality of effect. Being observational 
data, the potentially distorting effects of covariates, both measured and unmeasured, cannot be 
ignored and further evidence from extraneous datasets would be valuable. 
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Table 1: Frequency of observations in different subgroups of key categorical variables with corresponding  frequency and percentage of recorded 
varenicline prescription (Dataset 2, N=20,463). 
Variable N missing Subgroup n % prescribed 
varenicline 
Gender 0    
  Male 9740 25.0 % 
  Female 10723 22.4 % 
Age in years (mean = 44.8, S.D. 
= 15.6) 
0    
  13-19 996 5.6 % 
  20 - 39 6879 26.0 % 
  40 - 59 8557 25.5 % 
  60 - 89 4031 20.3 % 
Ethnicity 0    
  White (British & 
Irish) 
18253 24.0 % 
  White (other) 608 37.4 % 
  Asian 598 11.7 % 
  Black 392 12.1 % 
  Other 187 20.9 % 
  Unknown 425 16.2 % 
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Treatment 3321    
  NRT 13090 - 
  Varenicline 4052 - 
Setting 59    
  Community 8775 27.1% 
  GP practice 4829 31.9% 
  Other 1784 13.1% 
  Pharmacy 4392 14.7% 
  SSS 624 10.3% 
Year 0    
  2013 1010 6.9 % 
  2014 5207 13.1 % 
  2015 10578 28.5 % 
  2016 3668 27.7 % 
Quarter 0    
  Jan-Mar 6260 21.8 % 
  Apr-Jun 4425 26.4 % 
  Jul-Sep 5055 23.4 % 
  Oct-Dec 4723 24.1 % 
FTND (mean=4.68, S.D. = 2.24) 8626    
  0 479 20.1 % 
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  1 580 22.8 % 
  2 971 30.9 % 
  3 1537 27.7 % 
  4 1885 25.9 % 
  5 2022 27.9 % 
  6 1806 26.3 % 
  7 1287 23.6 % 
  8 792 21.4 % 
  9 367 21.1 % 
  10 111 20.9 % 
Deprivation index (mean = 
6.54, S.D. = 2.73) 
1687    
  1 732 38.8% 
  2 1088 34.7% 
  3 1560 32.3% 
  4 1668 30.2% 
  5 1674 27.5% 
  6 1725 24.0% 
  7 1850 29.0% 
  8 2508 24.0% 
  9 2938 16.1% 
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  10 3033 17.3% 
 
Table 2: Frequency of levels of factors which may be expected to influence choice of prescribed treatment. These frequencies are presented separately for 
clients prescribed (i) NRT (ii) varenicline. Figures derived from Dataset 2. 
 
Variable Category n/N (%) occurrence 
Live with other 
smoker(s)? 
 NRT varenicline 
 No  4995/8421 (59.3%) 1805/3021 (59.7%) 
 yes 3426/8421 (40.7%) 1216/3021 (40.3%) 
Live with children?    
 No 5427/8292 (65.4%) 1811/3021 (59.9%) 
 Yes 2865/8292 (34.5%) 1210/3021 (40.1%) 
Psychological condition?    
 No 11395/13090 (87.1%) 3695/4052 (91.2%) 
 Yes 1695/13090 (12.9%) 357/4052 (8.8%) 
Heart condition?    
 No 12564/13090 (96.0%) 3928/4052 (96.9%) 
 Yes 526/13090 (4.0%) 124/4052 (3.1%) 
Lung condition?    
 No 12031/13090 (91.9%) 3737/4052 (92.2%) 
 yes 1059/13090 (8.1%) 315/4052 (7.8%) 
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Table 3: Percentage quit rate (for categorical variables), model coefficients (both for main effects only and full model), odds ratios (adjusted for model 
covariates) and significance test results for all main effects and interactions included in the optimal GLMM, at 4 weeks after quit date. Model results are 
based on analyses of supplemented data incorporating imputed values (N=15,640). 
    Multiple regression model 
Variable  Quit rate - n/N (%) B 
(main 
effects 
only) 
Β (logit) Adjusted OR (95% 
CI) 
Wald-statistic 
(d.f.) 
p-value 
Gender      1.7 (1) 0.2 
 Male 4257/7523 (56.6%) 0 0 1   
 Female 4504/8117 (55.5%) -0.043 -0.044 0.96 (0.90,1.02)   
Age      117.3 (3) <0.001 
 13-19 338/860 (39.3%) 0 0 1   
 20-39 2896/5355 (54.1%) 0.59 0.57 1.77 (1.51,2.08)   
 40-59 3674/6406 (57.4%) 0.73 0.72 2.05 (1.74,2.40)   
 60+ 1853/3019 (61.4%) 0.89 0.88 
2.41 (2.03,2.86) 
  
Treatment      87.5 (1) <0.001 
 NRT 5140/9748 (52.7%) 0 0 1   
 varenicline 2043/3059 (66.8%) 0.54 0.60 1.82 (1.61,2.06)   
Setting      114.8 (3) <0.001 
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 community 3960/6350 (62.4%) 0 0 1   
 GP practice 1836/3763 (48.8%) -0.57 -0.55 0.58 (0.52,0.64)   
 pharmacy 1918/3503 (54.8%) -0.16 -0.12 0.89 (0.80,0.98)   
 SSS 289/559 (51.7%) -0.34 -0.34 0.71 (0.57,0.89)   
 other 758/1465 (51.7%) -0.12 -0.12 0.88 (0.77,1.02)   
Year      79.8 (3) <0.001 
 2013 490/930 (52.7%) 0 0 1   
 2014 2746/4634 (59.3%) -0.31 -0.31 0.74 (0.62,0.87)   
 2015 5015/9016 (55.6%) -0.51 -0.50 0.60 (0.51,0.72)   
 2016 510/1060 (48.1%) -1.10 -1.10 0.33 (0.26,0.43)   
Quarter      60.7 (3) <0.001 
 1 1871/3287 (56.9%) 0 0 1   
 2 2317/3992 (58.0%) -0.27 -0.27 0.76 (0.67,0.86)   
 3 2429/4413 (55.0%) -0.44 -0.44 0.64 (0.57,0.72)   
 4 2144/3948 (54.3%) -0.38 -0.38 0.68 (0.61,0.77)   
FTND    -0.048 -0.048 0.95 (0.94,0.97) 32.0 (1) <0.001 
IMD (deprivation)   -0.052 -0.047 0.95 (0.94,0.97) 41.7 (1) <0.001 
Treatment*Setting      6.6 (4) 0.2 
 NRT*comm
unity 
2416/4067 (59.4%) - 0 1   
 NRT*GP 742/1763 (42.1%) - 0 1   
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practice 
 NRT*pharm
acy 
1150/2263 (50.8%) - 0 1   
 NRT*SSS 229/451 (50.8%) - 0 1   
 NRT*other 603/1204 (50.1%) - 0 1   
 varenicline 
*community 
1114/1539 (72.4%) - 0 1   
 varenicline 
*GP practice 
504/858 (58.7%) - -0.068 0.93 (0.77,1.13)   
 varenicline*
pharmacy 
261/419 (62.3%) - -0.25 0.78 (0.62,0.99)   
 varenicline*
SSS 
39/57 (68.4%) - 0.15 1.17 (0.66,2.08)   
 varenicline 
*other 
125/186 (67.2%) - 0.11 1.15 (0.79,1.58)   
Treatment*FTND        
 NRT*FTND  - 0 1 3.05 (1) 0.08 
 varenicline 
*FTND    
 - -0.03 0.97 (0.94,1.01)   
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Table 4: Percentage quit rate (for categorical variables), model coefficients (both for main effects only and full model), odds ratios (adjusted for model 
covariates) and significance test results for all main effects and interactions included in the optimal GLMM, at 12 weeks after quit date. Model results are 
based on analyses of supplemented data incorporating imputed values (N=14,273). 
    Multiple regression model 
Variable  Quit rate - n/N (%) B 
(main 
effects 
only) 
Β (logit) Adjusted OR (95% 
CI) 
Wald-statistic 
(d.f.) 
p-value 
Gender      10.1 (1) 0.001 
 Male 2076/6485 (30.3%) 0 0 1   
 Female 2041/7428 (27.5%) -0.12 -0.12 0.88 (0.82,0.95)   
Age      150.0 (3) <0.001 
 13-19 181/806 (22.5%) 0 0 1   
 20-39 1256/4901 (25.6%) 0.39 0.37 1.45 (1.19,1.78)   
 40-59 1737/5826 (29.8%) 0.68 0.66 1.94 (1.59,2.38)   
 60+ 943/2740 (34.4%) 0.97 0.96 
2.61 (2.11,3.22) 
  
Treatment      197.5 (1) <0.001 
 NRT 2562/8832 (29.0%) 0 0 1   
 varenicline 1274/2709 (47.0%) 0.77 0.95 2.58 (2.26,2.94)   
Setting      33.7 (4) <0.001 
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 community 1609/5769 (27.9%) 0 0 1   
 GP practice 867/3431 (25.3%) -0.36 -0.27 0.76 (0.67,0.87)   
 pharmacy 1034/3184 (32.5%) -0.088 0.063 1.06 (0.94,1.20)   
 SSS 225/559 (45.6%) 0.21 0.31 1.37 (1.08,1.73)   
 other 352/1330 (26.4%) -0.043 0.015 1.02 (0.85,1.21)   
Year      29.0 (2) <0.001 
 2013 418/932 (44.8%) 0 0 1   
 2014 1010/4639 (21.8%) -0.47 -0.45 0.64 (0.54,0.76)   
 2015 2689/8702 (30.9%) -0.32 -0.30 0.74 (0.62,0.89)   
Quarter      29.0 (3) <0.001 
 1 643/2231 (28.8%) 0 0 1   
 2 1278/4003 (31.9%) -0.05 -0.053 0.64 (0.54,0.76)   
 3 1139/4424 (25.7%) -0.29 -0.29 0.74 (0.62,0.89)   
 4 1057/3615 (29.2%) -0.11 -0.12 0.89 (0.78,1.02)   
FTND   -0.043 -0.044 0.96 (0.94,0.97) 24.9 (1) <0.001 
Deprivation   -0.043 -0.043 0.96 (0.94,0.97) 25.3 (1) <0.001 
Treatment*Setting      24.6 (4) <0.001 
 NRT*commu
nity 
880/3701 (23.8%) - 0 1   
 NRT*GP 
practice 
434/1562 (27.8%) - 0 1   
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 NRT*other 269/1091 (24.7%) - 0 1   
 NRT*pharma
cy 
776/2027 (38.3%) - 0 1   
 NRT*SSS 203/451 (45.0%) - 0 1   
 varenicline 
*community 
674/1348 (50%) - 0 1   
 varenicline 
*GP practice 
343/769 (44.6%) - -0.23 0.79 (0.64,0.98)   
 varenicline*
pharmacy 
152/367 (41.4%) - -0.63 0.53 (0.42,0.69)   
 varenicline*S
SS 
35/57 (61.4%) - -0.18 0.83 (0.47,1.46)   
 varenicline 
*other 
70/168 (41.7%) - -0.12 0.88 (0.61,1.27)   
 
 
